DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors with Over $500k in Losses of Class Action Against ImmunoCellular Therapeutics, Ltd. (IMUC) and Lead Plaintiff Deadline – June 30, 2017

NEW YORK, NY / ACCESSWIRE / June 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased ImmunoCellular securities between May 1, 2012 and December 11, 2013, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/imuc.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements. Specifically, In September 2011, ImmunoCellular hired a stock promotional firm, Lidingo Holdings, LLC, to increase the value of the Company’s shares. Consequently, investors were led to trust that ImmunoCellular’s clinical studies for ICT-107, its lead product candidate, were going well. On December 11, 2013, ImmunoCellular revealed that the primary endpoint for its ICT-107 Phase II study “did not reach statistical significance” and did not increase overall survival in patients diagnosed with glioblastoma multiforme. Following this news, ImmunoCellular stock dropped sharply. Then, on April 10, 2017, as part of a U.S. Securities & Exchange Commission proceeding, the Company’s former CEO, Manish Singh, admitted to participating “in a paid stock-touting scheme.”

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/imuc, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss of over $500k in ImmunoCellular, you have until June 30, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 466883